Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inion buys more time with job cuts

This article was originally published in Clinica

Executive Summary

Finnish biodegradable medical implants maker Inion has bought itself an additional month of commercial operations after a reduction in its workforce has enabled it to slow down its cash burn. The firm last Thursday (January 22) said it has cut 15 jobs – 19% of its workforce – from its Tampere base. The move will result in a one-time charge of €70,000 ($90,650) but save the company €500,000 in overall expenditure during 2009, and €640,000 on an annualised basis thereafter. Inion CFO Julien Cotta told Clinica the firm now has cash and cash equivalents to support operations until the end of the first quarter of 2009 – prior to the job cuts, Inion has said it had enough funds to last until February (see Clinica No 1329, p 17). Mr Cotta said the company was in advanced talks to raise more funds.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT042553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel